Navigation Links
Pace of New Drug Advances May Be Slowing, Study Finds

By Amy Norton
HealthDay Reporter

TUESDAY, June 4 (HealthDay News) -- The drugs emerging from clinical trials in recent years seem less impressive than those developed in decades gone by, a new review finds.

Looking at more than 300 studies done since 1966, researchers found that drugs under development these days are less likely to solidly outperform placebos -- the sugar pills or other inert substances against which new drugs are tested.

From 1966 to 1990, the average study drug was about four times as likely to achieve a particular outcome than a placebo. But in trials done since 2001, drugs were only 36 percent more likely than placebos to show a desired effect, researchers reported in the June issue of the journal Health Affairs.

The reasons for the "worrisome decline" are not clear, said lead researcher Dr. Mark Olfson, a professor of clinical psychiatry at Columbia University in New York City.

But it's possible, he said, that "much of the low-hanging fruit has already been picked. In other words, many of the easiest-to-discover effective treatments may have already been found."

Another possibility, though, is that drugs from days of yore were not as impressive as they seemed at the time.

Trials done today generally have a more rigorous design, and they may be producing fewer "spuriously inflated findings" compared to older clinical trials, Olfson said.

A researcher not involved in the work said the findings are interesting, but "raise more questions than answers."

"The study is not designed to tell us the causes," said Ted Kaptchuk, an associate professor of medicine at Harvard Medical School, and director of the university's program in placebo studies.

"Are the new drugs in the pipeline just not as good?" Kaptchuk asked. It's not clear. In part, he said, that's because other research has found that people in clinical trials these days are more likely to respond to the placebo compared to people in studies 20 or 30 years ago.

Researchers have dubbed that phenomenon "placebo drift," Kaptchuk said, but no one knows what's driving it.

One theory is that today, people in a trial testing an antidepressant, for example, may go in with strong beliefs about the effects of those drugs -- whereas people in a trial in 1990 may not have.

Patients in a clinical trial do not know whether they are receiving a real drug or a placebo. So if someone on a placebo believes they're getting the real drug and the drug is good, that could affect how they respond.

Of course, it's not that effective drugs are no longer emerging, said Jean Slutsky, director of the Center for Outcomes and Evidence, part of the Agency for Healthcare Research and Quality, the government agency that funded the study. "There have certainly been important treatment advances in recent years and we should expect that to continue," Slutsky said.

Many of today's widely used prescription drugs -- such as cholesterol-lowering statins and SSRI antidepressants -- were developed in the 1980s or '90s. Those years also saw some medical breakthroughs, such as the protease inhibitors that turned HIV infection into a manageable chronic disease for many.

But other top-selling drugs emerged in the past decade or so, including the schizophrenia drug Abilify, the reflux medication Nexium and the antidepressant and pain drug Cymbalta.

It's also not clear from the current findings whether the decline in drugs' effects exists only in certain areas of medicine and not in others, Olfson said.

He said the number of studies in different specialties was too small to make a comparison. For example, only a small percentage of the 315 trials tested cancer drugs, a field in which researchers currently are developing high-tech "targeted" drugs they hope will be more effective and less toxic than older chemo drugs.

Still, Olfson said, his findings suggest that researchers need to adjust their focus.

Instead of pouring everything into traditional clinical trials looking for the next blockbuster, he said, researchers also should do more so-called comparative effectiveness studies, which look at how existing treatments stack up in the real world.

"In practice, for example, one treatment may turn out to be much more effective than another because many more patients actually take it than the other treatment," Olfson said.

Slutsky agreed that comparative effectiveness studies are important. That kind of research, she said, "will help illuminate important distinctions among treatments and help decision-makers make informed decisions regarding treatments for particular conditions."

Kaptchuk said the findings underscore a need to better understand the placebo effect, including how it may be changing drugs' apparent performance in clinical trials. And on a broader level, he said, the results show how complicated scientific research is.

"People tend to think that, you do a scientific experiment and you get certainty," Kaptchuk said. "But it's a lot more complex than that."

More information

Learn more about clinical trials from the U.S. National Institutes of Health.

SOURCES: Mark Olfson, M.D., M.P.H., professor, clinical psychiatry, Columbia University, New York City; Ted Kaptchuk, associate professor, medicine, Harvard Medical School, Boston; Jean Slutsky, M.S.P.H., director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, Md.; June 2013 Health Affairs

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. NJ stroke researchers report advances in spatial neglect research at AAN Conference
2. NYU Langone experts present research, clinical advances at neurosurgeons meeting
3. Triple negative breast cancer symposium highlights current advances
4. Studies See Advances in Detecting, Treating Pancreatic Cancer
5. Hi-Tech Advances May Improve Diabetics Lives
6. Meeting in Jordan to educate medical professionals on latest advances in osteoporosis
7. Advances in ataxia research to be featured at USFs Innovative Learning and Simulation Center
8. Key research from the 2012 Breast Cancer Symposium highlights treatment advances for early breast cancer
9. Collegiate inventors honored for innovative science and technology advances
10. Research from ASCOS Quality Care Symposium shows advances and challenges in improving the quality of cancer care
11. USC Norris cancer research ranks among top clinical advances for 2012
Post Your Comments:
Related Image:
Pace of New Drug Advances May Be Slowing, Study Finds
(Date:11/25/2015)... ... 25, 2015 , ... In an ongoing Clinical Study conducted by an independent ... UV Angel is evaluating the efficacy of its product and its disinfection protocol. This ... beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical center ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of Pulmonary ... individuals and groups responsible for advancing care for pulmonary hypertension (PH) patients and ... the public, will receive special recognition throughout 2016 as part of PHA’s 25th ...
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also known ... people who find their cholesterol levels and weight are creeping up are more likely ... don’t have any of the other symptoms. , Thyroid hormone plays a major role ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to seek ... dental implants at her Mississauga, ON practice. Dr. Williams has been providing ... of dental implants. , Missing teeth can lead to a variety of complications ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)... Endo International plc (NASDAQ: ENDP ) (TSX: ... and CEO, will discuss corporate updates at the 27 th ... York on Wednesday, December 2, 2015 at 1 ... Relations, and then the link to the event. Participants should ... to visit the site and download any streaming media software ...
(Date:11/25/2015)... -- Developmental, commercial, and regulatory/legal strategies ... pharmaceutical products, says GBI Research . ... all play a key role in boosting the profitability ... . --> Developmental, commercial, and ... the profitability of pharmaceutical products, says GBI Research ...
Breaking Medicine Technology: